Surrozen (SRZN) Cash & Equivalents (2020 - 2026)
Surrozen (SRZN) recorded quarterly Cash & Equivalents of $106.9 million in Q1 2026, up 19.79% quarter-over-quarter from $89.2 million in Q4 2025, and up 5.18% on a YoY basis from $101.6 million in Q1 2025.
Surrozen (SRZN) Cash & Equivalents (2020 - 2026) Analysis & Trends
Surrozen's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $106.9 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 5.18% year-over-year to $106.9 million; the TTM figure through Mar 2026 stood at $106.9 million (up 5.18% YoY), while the FY2025 annual figure was $89.2 million, up 158.19% from the prior year.
- Cash & Equivalents was $106.9 million for Q1 2026 at Surrozen, up from $89.2 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $106.9 million in Q1 2026 to a low of $14.3 million in Q1 2022.
- Historically, Cash & Equivalents has averaged $48.0 million across 5 years, with a median of $34.6 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Cash & Equivalents tumbled 58.21% in 2022, then jumped 272.46% in 2025.
- A 5-year view of Cash & Equivalents shows it stood at $24.7 million in 2022, then jumped by 45.98% to $36.0 million in 2023, then declined by 4.1% to $34.6 million in 2024, then jumped by 158.19% to $89.2 million in 2025, then advanced by 19.79% to $106.9 million in 2026.
- The last three Cash & Equivalents figures came in at $106.9 million (Q1 2026), $89.2 million (Q4 2025), and $81.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 1.91 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 2.77 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 18.44 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 7.15 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 5.49 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 558.94 Mn |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | 106.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 106.91 Mn |
| Dec 31, 2025 | 89.25 Mn |
| Sep 30, 2025 | 81.30 Mn |
| Jun 30, 2025 | 90.40 Mn |
| Mar 31, 2025 | 101.65 Mn |
| Dec 31, 2024 | 34.57 Mn |
| Sep 30, 2024 | 31.01 Mn |
| Jun 30, 2024 | 37.77 Mn |
| Mar 31, 2024 | 27.29 Mn |
| Dec 31, 2023 | 36.04 Mn |
| Sep 30, 2023 | 33.98 Mn |
| Jun 30, 2023 | 36.50 Mn |
| Mar 31, 2023 | 27.81 Mn |
| Dec 31, 2022 | 24.69 Mn |
| Sep 30, 2022 | 25.53 Mn |
| Jun 30, 2022 | 16.87 Mn |
| Mar 31, 2022 | 14.31 Mn |
| Dec 31, 2021 | 33.09 Mn |
| Sep 30, 2021 | 61.10 Mn |
| Jun 30, 2021 | 18.85 Mn |